Sanctuary Advisors LLC Acquires New Stake in Illumina, Inc. $ILMN

Sanctuary Advisors LLC bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 19,356 shares of the life sciences company’s stock, valued at approximately $3,403,000.

Other institutional investors have also added to or reduced their stakes in the company. Empowered Funds LLC boosted its position in shares of Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after acquiring an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC bought a new position in shares of Illumina in the second quarter worth approximately $621,000. CW Advisors LLC purchased a new stake in Illumina in the second quarter valued at approximately $275,000. Marshall Wace LLP lifted its position in Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after purchasing an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC lifted its position in Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after purchasing an additional 1,748 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Sanford C. Bernstein restated a “market perform” rating and set a $215.00 price objective on shares of Illumina in a research report on Friday, July 31st. Citigroup increased their target price on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a research note on Monday, August 3rd. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Deutsche Bank Aktiengesellschaft cut Illumina to a “hold” rating in a report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. upped their target price on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $188.40.

Insider Buying and Selling

In other Illumina news, Director Keith A. Meister sold 457,858 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,095,958 shares of company stock valued at $401,720,974 over the last three months. Corporate insiders own 2.90% of the company’s stock.

Illumina Trading Up 0.8%

Shares of ILMN opened at $224.99 on Wednesday. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $33.97 billion, a P/E ratio of 41.98, a PEG ratio of 3.14 and a beta of 1.45. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $226.84. The firm has a fifty day simple moving average of $190.35 and a two-hundred day simple moving average of $153.78.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the company earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.